Aehr (AEHR) Q1 2025 Earnings Call Transcript

Aehr Test reported Q1 fiscal 2025 revenue of $13.1M, down 36% year-over-year, driven primarily by WaferPak sales of $12.1M (92% of revenue). Non-GAAP gross margin improved to 54.7% (from 48.7%), non-GAAP net income was $2.2M ($0.07/share) vs $5.2M ($0.18) a year ago, backlog stood at $16.6M, and cash was $40.8M after a $10.6M cash payment for the Incal acquisition. Management reaffirmed fiscal 2025 guidance of at least $70M revenue and pre-tax profit of at least 10% of revenue, and highlighted expanding market opportunities in silicon carbide, GaN, AI processors, NAND flash and HDDs alongside initial volume orders and integration progress from the Incal acquisition.

Analysis

Aehr’s win density is shifting from lumpy system orders to high-frequency WaferPak sales and a newly acquired packaged-part franchise — that mix creates a near-term margin tailwind and a smoother revenue cadence because Incal’s orders sit further into the booking curve. The key operational lever to watch is consolidation risk: Fremont capacity and ERP migration compress near-term execution slack but any hiccup will show up as delayed shipments because Incal’s lead times are longer and more binding.

Silicon-carbide and AI-processor ramps are binary, multi-quarter catalysts: a single committed wafer-level production buy from a hyperscaler or an AI-accelerator could represent low-double-digit revenue share in the coming 12 months and materially higher in 18–36 months. Conversely, the biggest single reversal risk is timing — fab and module capacity expansions currently penciled for calendar 2025; a six-month slippage in those capital plans would disproportionately hit expectation-driven multiple expansion.

Competitively, Aehr is uniquely leveraged to any acceleration in co-packaged optics/AI interconnect adoption because its 3.5kW wafer-level platform is reusable across silicon carbide, GaN, flash and high-power AI processors — that cross-market optionality is underappreciated. The balance-sheet is adequate for integration but the planned S-3 and history of short lead-time revenue imply potential future dilution if multiple large production ramps require working-capital financing faster than cash generation.

Key Decisions for Investors

• Long AEHR (stock) or 12–18 month LEAP calls: enter on any pullback toward the prior quarter's post-close level; R/R: asymmetric — a confirmed production buy from one major AI or SiC customer could double revenue contribution in 12 months; downside protected by ~$40M cash runway but monitor S-3 filing (dilution tail risk).
• Buy AEHR Jan-2026 LEAP calls and hedge ~20–30% notional with short NVDA (near-term puts) — rationale: keep upside to company-specific SiC/AI wins while hedging broad AI-cycle downside that would simultaneously pressure AEHR; rebalance after any announced production commitments.
• Covered-call income trade for conservative exposure: buy AEHR stock and sell 3–6 month calls at ~25% OTM to collect premium through integration; use proceeds to fund potential follow-on WaferPak demand spikes. Monitor backlog disclosures and Incal shipment confirmations as early exit signals.
• Event-driven short: establish a small-duration short/put position if Aehr misses a quarter’s backlog transparency or delays Fremont consolidation/ERP go-live — catalyst window: next two quarters; risk: binary upside from large production wins can spike shares, keep position size small.